Cover Image
市場調查報告書

A型流感病毒H5N1亞型感染疾病:開發平台分析

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 398830
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
A型流感病毒H5N1亞型感染疾病:開發平台分析 Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 151 Pages
簡介

H5N1流感病毒的型,稱作禽流感,是感染性非常高,危及生命的呼吸疾病。該病毒也傳染給人類。症狀有發燒,咳嗽,急性呼吸困難,呼吸急促、呼吸困難,腹痛及腹瀉等。原因有處理雞肉,碰感染的鳥類,吃生的或烤半熟的雞肉等。治療使用抗病毒藥物。

本報告提供A型流感病毒H5N1亞型感染疾病的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

A型流感病毒H5N1亞型感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

在大學/研究機關研究中的產品

開發治療藥的企業

  • Akshaya Bio Inc
  • Altimmune Inc
  • Antigen Express Inc
  • Aphios Corp
  • BioDiem Ltd
  • BiondVax Pharmaceuticals Ltd
  • CEL-SCI Corp
  • Cocrystal Pharma Inc
  • Emergent BioSolutions Inc
  • Gemmus Pharma Inc
  • GlaxoSmithKline Plc
  • Hemispherx Biopharma Inc
  • iBio Inc
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Kineta Inc
  • Lakewood-Amedex Inc
  • Medicago Inc
  • Medigen Vaccine Biologics Corp.
  • Microbiotix Inc
  • NanoBio Corp
  • Nanotherapeutics Inc
  • NanoViricides Inc
  • NewLink Genetics Corp
  • OPKO Health Inc
  • PaxVax Inc
  • PeptiDream Inc
  • Protein Sciences Corp
  • Shionogi & Co Ltd
  • Takeda Pharmaceutical Company Ltd
  • TechnoVax Inc
  • TGV-Laboratories
  • Vaxart Inc
  • Vaxine Pty Ltd
  • VaxInnate Corp
  • Visterra Inc

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9685IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H5N1 Subtype Infections - Overview
    • Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc
    • Altimmune Inc
    • Antigen Express Inc
    • Aphios Corp
    • BiondVax Pharmaceuticals Ltd
    • CEL-SCI Corp
    • Cocrystal Pharma Inc
    • Curevac AG
    • Gemmus Pharma Inc
    • GlaxoSmithKline Plc
    • Hemispherx Biopharma Inc
    • iBio Inc
    • Inovio Pharmaceuticals Inc
    • Johnson & Johnson
    • Kineta Inc
    • Lakewood-Amedex Inc
    • Medicago Inc
    • Medigen Vaccine Biologics Corp
    • Microbiotix Inc
    • NanoBio Corp
    • Nanotherapeutics Inc
    • NanoViricides Inc
    • OPKO Health Inc
    • PaxVax Inc
    • PeptiDream Inc
    • Shionogi & Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • TechnoVax Inc
    • Vaxart Inc
    • Vaxine Pty Ltd
    • Visterra Inc
  • Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
    • A-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AE-AI vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alferon LDO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beraprost sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-42344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHOS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GP-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GP-1681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GREFLU/VIE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HAI-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-36.6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Influ-nRNA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-3510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lalistat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-2329 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-2546 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MV-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nasovax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Influenza Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pimodivir hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNSIA-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNSIA-49 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXVX-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-033188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Sirtuin for Influenza - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVX-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VGX-3400X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VH-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
      • Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
      • Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant
      • Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
      • Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
      • Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
      • Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza
      • Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.
      • Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine
      • Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line
      • Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting
      • Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company's Universal Flu Vaccine
      • Jan 21, 2014: BiondVax's universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8
      • Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO
      • Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top